Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
  • A61K31/365—Lactones
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2004—Excipients; Inactive ingredients
  • A61K9/2022—Organic macromolecular compounds
  • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2004—Excipients; Inactive ingredients
  • A61K9/2022—Organic macromolecular compounds
  • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
  • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2004—Excipients; Inactive ingredients
  • A61K9/2022—Organic macromolecular compounds
  • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
  • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing

Definitions

• the invention encompasses delayed release pharmaceutical compositions comprising mycophenolic acid, a pharmaceutically acceptable salt thereof or combinations thereof, and methods for making the same.
• Mycophenolic acid was first isolated in the 19th century and has reported activity as an anti-tumor, anti-viral, immunosuppressive, anti-psoriatic, and anti-inflammatory agent.
• mycophenolate sodium is chemically named (E)-6-(4-hydroxy-6- methoxy-7-mrthyl-3-oxo-l ,3-dihydro-isobenzofuran-5-yl)-4-methylhex-4-enoic acid sodium salt. Its empirical formula is CnHigOeNa. The molecular weight is 342.32 and the structural formula is:
• Mycophenolate sodium is a white to off-white, crystalline powder and is highly soluble in aqueous media at physiological pH and practically insoluble in 0.1N hydrochloric acid.
• U.S. patent No. 6,025,391 describes pharmaceutical compositions which have been modified to release pharmaceutically acceptable mycophenolate salt in the upper part of the intestinal tract and methods of treatment using the pharmaceutical compositions.
• the patent discloses a pharmaceutical composition comprising an enteric coated pharmaceutically acceptable mycophenolate salt.
• An enteric coated capsule containing particles of mycophenolate sodium mixed with silicon dioxide, lactose and magnesium stearate is exemplified.
• U.S. patent No. 6,172,107 describes a pharmaceutical composition comprising a mycophenolate salt, the composition being adopted to release mycophenolate in the upper part of the intestinal tract.
• the delayed release of the active ingredient is provided by compositions having an enteric coating.
• U.S. patent No. 6,306,900 describes a pharmaceutical composition comprising a mycophenolate salt, the composition being adopted to release mycophenolate in the upper part of the intestinal tract.
• the delayed release of the active ingredient is provided by compositions having an enteric coating.
• the supporting examples are enteric coated capsules.
• U.S. patent application No. 2005/0013859 describes a solid dosage form, e.g. a tablet, comprising mycophenolic acid or mycophenolate salt and a process for its production.
• US 2005/0013859 describes both accelerated and delayed release compositions. Tablets comprising an enteric coating and a pharmacologically effective amount of mycophenolic acid or mycophenolate salt, wherein the mycophenolic acid or mycophenolate salt is present in an amount of from about 20% to about 95% by weight based on the total weight of the tablet including the enteric coating are exemplified.
• WO 2007/093346 describes the use of mycophenolic acid in immunosuppression, particularly for prevention or treatment of transplant rejection and immuno-mediated and/or inflammatory diseases, wherein mycophenolic acid, the salt or the prodrug thereof is administered with an initial intensified dosage regimen.
• WO 2007/093346 describes the use of an enteric coated composition containing mycophenolate, or a salt or a prodrug thereof in the manufacture of a medication, whereby the dosage of mycophenolate during the first week to the first three months of treatment is up to about 3-fold the standard dosage of mycophenolate, and then mycophenolate is administered at standard daily dosage of mycophenolate.
• WO 2009/047799 describes high dose solid unit oral pharmaceutical dosage form compositions comprising mycophenolate sodium as active agent in an amount of from greater than 720 mg to about 1500 mg and one or more pharmaceutically acceptable excipients(s). Particularly the dosage forms are meant for once a day or twice a day administration and provide the active agent in extended release form which is released in a sustained manner in- vivo for a prolonged duration.
• Mycophenolate sodium is commercially available as enteric coated delayed-release tablets sold by Novartis under the trade name Myfortic®.
• Myfortic® delayed-release tablets are an enteric formulation of mycophenolate sodium that deliver the active moiety mycophenolic acid.
• Myfortic® is available for oral use as delayed-release tablets containing either 180 mg or 360 mg of mycophenolate sodium.
• a derivative of mycophenolate, mycophenolate mofetil, has been developed and is commercially available in the United States under the trade name CellCept®.
• a delayed release pharmaceutical composition comprising an active pharmaceutical ingredient selected from mycophenolic acid, a pharmaceutically acceptable salt thereof or combinations thereof, wherein said delayed release is matrix controlled.
• the pharmaceutical composition comprises a matrix, wherein the matrix comprises an active pharmaceutical ingredient, and an enteric polymer.
• the active pharmaceutical ingredient is selected from mycophenolic acid, a pharmaceutically acceptable salt thereof or combinations thereof, such as mycophenolate sodium or mycophenolate mofetyl.
• the pharmaceutical composition is in the form of a tablet.
• the enteric polymer is preferably selected from the group consisting of acrylic resins such as methacrylate copolymers, hydroxypropylmethyl cellulose phthalate, hydroxypropylmethyl cellulose acetate succinate and polyvinylacetate phthalate.
• the pharmaceutical composition may comprise an active pharmaceutical ingredient, an enteric polymer, and a disintegrant.
• a process for preparing a delayed release pharmaceutical composition comprising combining an active pharmaceutical ingredient and an enteric polymer to provide a pharmaceutical composition matrix.
• an active pharmaceutical ingredient which is preferably mycophenolate sodium, with an enteric polymer and optionally one or more pharmaceutical acceptable excipients;
• step (ii) admixing the granules obtained from step (i) with one or more further pharmaceutical excipients;
• step (iii) compressing the mixture obtained from step (ii) into tablets.
• an active pharmaceutical ingredient which is preferably mycophenolate sodium
• a diluent which is preferably lactose monohydrate
• a suspending agent which is preferably silicon dioxide
• a disintegrant which is preferably sodium starch glycloate
• step (c) wet granulating the mixture obtained from step (i) using the granulation solution from step (ii), preferably drying the resulting granules;
• step (d) mixing the granules from step (c) with a disintegrant, which is preferably sodium starch glycolate, and/or a lubricant, which is preferably magnesium stearate;
• a disintegrant which is preferably sodium starch glycolate, and/or a lubricant, which is preferably magnesium stearate;
• step (e) compressing the mixture from step (d) into tablets.
• Delayed release in the context of the present invention means that the composition releases the active pharmaceutical ingredient(s) after passing through the stomach.
• the delayed release compositions of the present invention release the active pharmaceutical ingredient(s) in the upper tract of the intestine.
• no dissolution of the composition occurs in the stomach.
• Such a dissolution profile can be tested in vitro using a dissolution test detailed in the Examples section below.
• the compositions of the invention do not disintegrate for at least two hours when tested in artificial gastric juices such as 0.1N HC1 of pH 1, and thereafter releases a substantial portion e.g. at least 60%, preferably more than 75%, of the labeled amount of active pharmaceutical ingredient(s) within 60 minutes in artificial intestinal juices such as phosphate buffer at pH 6.8.
• the present invention provides a delayed release pharmaceutical composition
• a delayed release pharmaceutical composition comprising an active pharmaceutical ingredient, wherein said delayed release is matrix controlled (rather than coating controlled).
• the pharmaceutical composition comprising a matrix, wherein the matrix comprises mycophenolic acid or a pharmaceutically acceptable salt thereof, and an enteric polymer.
• the pharmaceutical composition is a delayed release composition.
• the delayed release compositions do not release the active ingredient in the stomach but release of the active ingredient occurs distal to the stomach, preferably, in the intestines (usually the upper tract of the intestines). Preferably, not more than 5% of the active ingredient contained therein occurs in the stomach. Preferably, release of the active ingredient in the intestines is immediate, or within one hour.
• This delayed release profile is achieved by designing the composition so that it does not dissolve/disintegrate in the stomach but does dissolve/disintegrate in the intestines.
• the stomach is an acidic environment (approximately pH ⁇ 3) whereas the intestines are a more basic environment (approximately pH ⁇ 5.5 and above).
• the conditions of the stomach/intestines can therefore be replicated in vitro.
• the pharmaceutical compositions of the invention do not release the active pharmaceutical ingredient for at least two hours in artificial gastric juices such as HC1 of pH 1, and thereafter release a substantial portion e.g. at least 60%, preferably more than 75%, of active pharmaceutical ingredient within 60 minutes in artificial intestinal juices such as phosphate buffer at pH 6.8.
• the active pharmaceutical ingredient in the context of the present invention, is selected from the list comprising mycophenolic acid, a pharmaceutically acceptable salt thereof and combinations thereof, such as mycophenolate sodium or mycophenolate mofetyl. Most preferably, the active pharmaceutical ingredient is mycophenolate sodium.
• the active pharmaceutical ingredient is present in an amount greater than about 50%), more preferably between about 55% and about 99%, more preferably between about 60%) and about 75%, most preferably between about 64% and about 71%, by weight (w/w) of the pharmaceutical composition.
• the pharmaceutical compositions of the invention are preferably in the form of a tablet. Tablets of the present invention preferably exclude an enteric coating. This does not preclude any other type of coating being used however in a preferred embodiment, the tablets of the present invention exclude a coating (of any type), i.e. the pharmaceutical composition does not comprise a coating.
• the pharmaceutical compositions can be prepared using any conventional process. In particular, a matrix comprised of granulated pharmaceutical compositions is preferred.
• the compositions can be prepared by conventional granulation techniques such as wet granulation. For example, the compositions can be prepared by wet granulation techniques applying high shear granulators. Accordingly, wet granulated compositions are preferred.
• the matrix comprises an intra-granular portion and an extra-granular portion.
• the enteric polymer employed in the present invention controls the location in the digestive system where the pharmaceutical composition dissolves and/or disintegrates.
• the enteric polymer is not affected by the acidic environment observed in the stomach area.
• Suitable enteric polymers include acrylic resins such as methacrylate copolymers, hydroxypropylmethyl cellulose phthalate, hydroxypropylmethyl cellulose acetate succinate, polyvinylacetate phthalate and combinations thereof.
• the methacrylate copolymers may be methacrylic acid - methyl methacrylate (1 : 1) copolymers which are commercially available from Rohm GmbH & Co. KG in the "Eudragit L series of polymers" which dissolve at pH 5-6.
• the enteric polymer may be methacrylic acid - methyl methacrylate (1 :2) copolymers which are commercially available from Rohm GmbH & Co. KG in the "Eudragit S series of polymers" which dissolve at pH greater than 6. Also, combinations of methacrylic acid - methyl methacrylate (1 : 1) copolymers and methacrylic acid - methyl methacrylate (1 :2) are useful in the present invention.
• the most preferred enteric polymers are hydroxypropylmethyl cellulose phthalate and polyvinyl acetate phthalate.
• the amount of enteric polymer is less than about 50%, more preferably between about 0.5%> and about 30%>, more preferably between about 1%> and about 20%>, more preferably between about 5%> and about 15%>, most preferably between about 8%> and about 10% by weight (w/w) of the pharmaceutical composition.
• compositions of the present invention may also comprise one or more further pharmaceutically acceptable excipients selected from, but not limited to, disintegrants, binders, diluents, lubricants, glidants, suspending agents, plasticizers, emulsifying agents, sweetening agents, flavouring agents, and pigments.
• Disintegrants are particularly preferred in any composition of the present invention. Disintegrants assist the break up of the composition in the intestine.
• Suitable disintegrants include, but are not limited to, alginic acid, calcium phosphate (tribasic), carboxymethylcellulose calcium, carboxymethylcellulose sodium, powdered cellulose, chitosan, colloidal silicon dioxide, croscarmellose sodium (crosslinked carboxymethyl cellulose sodium), crospovidone, docusate sodium, guar gum, hydroxypropyl cellulose, low- substituted hydroxypropyl cellulose, magnesium aluminium silicate, methylcellulose, microcrystalline cellulose, sodium alginate, sodium starch glycolate, starch, pregelatinized starch, and combinations thereof.
• Preferred disintegrants in any embodiment of the present invention are crospovidone, croscarmellose sodium, and sodium starch glycolate.
• the disintegrant is present in an amount of about 1% to about 8%, more preferably about 3% to about 6.5%, more preferably about 4% to about 6%, most preferably about 4% by weight (w/w) of the pharmaceutical composition.
• the disintegrant may be an intra-granular excipient, an extra-granular excipient or a combination of both intra-granular and extra-granular excipients.
• an intra-granular excipient is an excipient that is part of the granulated composition, i.e. the excipient is incorporated at the granulation phase of the process preparing a pharmaceutical composition.
• an extra-granular excipient refers to an excipient that is not included in the granulate used to prepare the pharmaceutical composition but is added in the process preparing the pharmaceutical composition to the granulate, after its formation, in a subsequent process step.
• a disintegrant is present in an amount of about 1%) to about 6%), more preferably about 3% to about 5%, most preferably about 4% by weight (w/w) of the pharmaceutical composition.
• a disintegrant is present in an amount greater than about 1%, preferably of about 1% to about 6%, more preferably about 3% to about 5%, most preferably about 3.5% to about 4.5% by weight (w/w) of the pharmaceutical composition.
• a disintegrant is included as both an intra-granular excipient and an extra-granular excipient.
• a disintegrant is present as an intra-granular excipient in an amount of about 1%) to about 6%, more preferably about 3% to about 5%, most preferably about 4% by weight (w/w) of the pharmaceutical composition, and a disintegrant as an extra-granular excipient in an amount of about 1% to about 3%, more preferably about 2% by weight (w/w) of the pharmaceutical composition.
• Suitable binders include, but are not limited to, acacia, alginic acid, carbomer copolymer, carbomer interpolymer, copovidone, microcrystalline cellulose, dextrin, ethylcellulose, gelatin, glucose (liquid), guar gum, hydroxypropyl cellulose, maltose, methylcellulose, polyethylene oxide, polyvinylpyrrolidone, povidone, starch, sodium carboxymethylcellulose and combinations thereof.
• Suitable diluents used in the composition include, but are not limited to, calcium carbonate, calcium phosphate (dibasic and/or tribasic), calcium sulfate, microcrystalline cellulose, dextrates, dextrin, dextrose excipient, daolin, lactitol, lactose (anhydrous and/or monohydrate), maltose, mannitol, microcrystalline cellulose, sorbitol, starch, titanium dioxide, sucrose and combinations thereof.
• the diluent is lactose, starch or titanium dioxide.
• the diluent is present in an amount of about 1% to about 50%, more preferably about 1% to about 20%, more preferably about 5% to about 15%, more preferably about 10% to about 12% by weight (w/w) of the pharmaceutical composition.
• a diluent may be included either as an intra-granular excipient or as an extra-granular excipient.
• the diluent is preferably lactose monohydrate.
• the diluent is preferably starch.
• Suitable lubricants which can optionally be used in the composition include, but are not limited to sodium lauryl sulfate, calcium stearate, glyceryl behenate, magnesium stearate, polyethylene glycol, sodium stearyl fumarate, stearic acid, talc, or zinc stearate.
• Preferred lubricants include sodium lauryl sulfate, magnesium stearate or stearic acid.
• the most preferred lubricant is magnesium stearate.
• the lubricant is present in an amount of about 0.5% to about 5%, more preferably about 0.5%) to about 3% by weight (w/w) of the compositions.
• Suitable glidants used in the compositions include, but are not limited to, talc, kaolin, glycerol monostearate, silicic acid, magnesium stearate, titanium dioxide and combinations thereof.
• the glidant is present in an amount of between about 0% and about 5%.
• Suitable suspending agents used in the compositions include, but are not limited to, colloidal silicon dioxide.
• the suspending agent is present in an amount of about 1% to about 10%, more preferably about 1.5% to about 5%, most preferably about 2% to about 3% by weight (w/w) of the pharmaceutical composition.
• Suitable plasticizers used in the compositions include, but are not limited to, triethyl citrate, triacetin, dibutyl sebacate, diethyl phthalate, and combinations thereof.
• the plasticizer is present in an amount of about 0% to about 5%, more preferably about 0.5% to about 1.5%, by weight (w/w) of the pharmaceutical composition.
• Suitable emulsifying agents used in the compositions include, but are not limited to, stearic acid, oleic acid, palmitic acid, esters of glycerol and fatty acids such as glycerol monostearate, acacia, gums such as guar gums, lecithin and combinations thereof.
• the emulsifying agent is present in an amount of about 0%) to about 5%, more preferably about 0.5% to about 1.5%, by weight (w/w) of the pharmaceutical composition.
• suitable sweetening agents, flavouring agents, pigments or combination thereof used in the compositions.
• the composition preferably comprises mycophenolate sodium and hydroxypropylmethyl cellulose phthalate (enteric polymer) or mycophenolate sodium and polyvinyl acetate phthalate (enteric polymer).
• the composition preferably comprises mycophenolate sodium, hydroxypropylmethyl cellulose phthalate (enteric polymer), and sodium starch glycolate (disintegrant).
• the process of the present invention comprises combining an active pharmaceutical ingredient and an enteric polymer to provide a pharmaceutical composition matrix.
• compositions of the present invention can be prepared by any conventional technique.
• the compositions can be prepared using techniques such as direct compression, wet granulation, and dry granulation.
• the enteric polymers maybe incorporated as dry powders or through concentrated solutions in organic media.
• the compositions can be prepared using granulation techniques.
• the compositions are prepared using wet granulation.
• the pharmaceutical composition in which the pharmaceutical composition is a tablet the invention provides a process for preparing a pharmaceutical composition of the invention comprising:
• step (ii) admixing the granules obtained from step (i) with one or more further pharmaceutical excipients;
• step (iii) compressing the mixture obtained from step (ii) into tablets.
• Suitable excipients useful in step (i) include, but are not limited to, diluents and/or suspending agents (as described above).
• step (i) a mixture of the active pharmaceutical ingredient and one or more pharmaceutical acceptable excipients may be prepared before the enteric polymer is added.
• step (i) involves wet granulating an active pharmaceutical ingredient with an enteric polymer and optionally one or more pharmaceutical acceptable excipients.
• any granulation solution can be employed.
• the granulation solution is organic, more preferably the organic granulation solution comprises ethanol and/or acetone, most preferably the granulation solution is ethanol (95%) and/or acetone.
• the granulation solution preferably contains the enteric polymer. The enteric polymer is therefore introduced into the pharmaceutical composition via the granulation solution.
• the solution is preferably added gradually, for example added over a period of 2-3 minutes.
• step (i) above is a wet granulation process
• the resulting wet mass obtained from the granulation process is preferably dried before the granules are mixed in step (ii). More preferably, the resulting wet mass is dried until the moisture content is less than about 2% by weight.
• the resulting granules may be sieved prior to step (ii) in order to provide particles in a selected size range.
• the particle size can be selected so that 80-100%, preferably 90-100%, more preferably 100% of the granules have a particle size less than about 800 microns.
• step (ii) the mixture is preferably compressed into tablets having a hardness of 10 SCU (Strong Cobbs Unit) or more, preferably 15 SCU or more, more preferably 20 SCU or more, most preferably about 20 SCU.
• 10 SCU String Cobbs Unit
• an active pharmaceutical ingredient which is preferably mycophenolate sodium
• a diluent which is preferably lactose monohydrate
• a suspending agent which is preferably silicon dioxide
• a disintegrant which is preferably sodium starch glycloate
• step (c) wet granulating the mixture obtained from step (i) using the granulation solution from step (ii), preferably drying the resulting granules;
• step (d) mixing the granules from step (c) with a disintegrant, which is preferably sodium starch glycolate, and/or a lubricant, which is preferably magnesium stearate;
• a disintegrant which is preferably sodium starch glycolate, and/or a lubricant, which is preferably magnesium stearate;
• step (e) compressing the mixture from step (d) into tablets.
• Example 1 Wet granulation; HPMCP as enteric polymer with ex-granular disintegrant
• Mycophenolate Sodium, Silicon dioxide and Lactose anhydrous were mixed into a blend with a high shear mixer for one minute.
• the blend was further granulated with gradual addition of enteric polymer containing granulation solution for a few minutes.
• the granulation solution was prepared by mixing hydroxypropylmethyl cellulose phthalate with a solvent mixture of ethanol and acetone.
• the resulting wet mass was dried in a Fluid Bed Dryer at a nominal temperature of 50°C till the moisture content was less than about 2%, and sieved to provide particles in a selected size range.
• Example 1 The resulting granules (90% below 710 ⁇ ) were mixed with sodium starch glycolate and magnesium stearate and compressed into oval tablets having a hardness of about 20 SCU (Strong Cobbs Unit). Table 1 summarizes the composition of the tablets of Example 1.
• Example 2 Wet granulation; HPMCP as enteric polymer with both ex- and intra- granular disintegrant
• Table 3 Formulation of Tablets of Exam le 3 b wei ht m .
• Mycophenolate Sodium, Silicon dioxide and Lactose anhydrous were mixed into a blend with a high shear mixer for one minute.
• the blend was further granulated with gradual addition of enteric polymer containing granulation solution for a few minutes.
• the granulation solution was prepared by mixing hydroxypropylmethyl cellulose phthalate with a solvent mixture of ethanol and acetone.
• the resulting wet mass was dried in a Fluid Bed Dryer at a nominal temperature of 50°C till the moisture content was less than about 2%, and sieved to provide particles in a selected size range.
• the resulting granules (90% below 710 ⁇ ) were mixed with starch and magnesium stearate and compressed into oval tablets having a hardness of about 15 SCU.
• Table 4 Formulation of Tablets of Example 4 by weight [mg].
• Example 5 (Dry granulation; HPMCP as enteric polymer)
• Mycophenolate Sodium, Silicon dioxide, Lactose anhydrous, hydroxypropylmethyl cellulose phthalate and magnesium stearate are mixed into a blend with a high shear mixer for three minutes.
• the blend is then compacted applying a slugging tooling equipped tablet press machine or, alternatively, by roller compaction followed by low shear milling to obtain a uniformly sized granulate.
• This milled granulate is then mixed with sodium starch glycolate and magnesium stearate and compressed into oval tablets applying a tablet press machine.
• Table 5 Formulation of Tablets of Example 5 by weight [mg].
• Tablets of the formulations of Examples 1-4 were dissolved for 120 min in acid medium followed by 60 min in buffer conditions.
• the acid medium was composed of 750 ml 0.1 N HCl at 37°C and 100 RPM, whereas the buffer was 1000 ml Phosphate buffer at pH 6.8, 37°C and 100 RPM (concentrated phosphate buffer was added to acid stage medium).
• the drug release profile was measured at the end of the acid stage (120 min) and after 130, 135, 140, 165 and 180 min in the buffer stage.
• Table 6 summarizes the dissolution data for Examples 1-4, their details are provided in Tables 1-4.
• compositions of the invention exhibit a dissolution profile in which no, or virtually no, dissolution of the compositions occurs at low pH (i.e. simulating conditions in the stomach) and in which rapid dissolution of the compositions occurs at higher pH (i.e. simulating conditions in the upper tract of the intestines).

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Medicinal Preparation (AREA)

Priority Applications (4)

Applications Claiming Priority (1)

Publications (1)

Family

ID=41683056

Family Applications (1)

Country Status (4)

Cited By (1)

Citations (7)

• 2009
  • 2009-10-13 WO PCT/US2009/060551 patent/WO2011046546A1/en active Application Filing
  • 2009-10-13 EP EP09737509A patent/EP2488173A1/de not_active Withdrawn
  • 2009-10-13 EA EA201270544A patent/EA201270544A1/ru unknown
• 2012
  • 2012-03-29 IL IL218947A patent/IL218947A0/en unknown

Patent Citations (7)

Also Published As

Similar Documents

Legal Events